Arcutis Biotherapeutics Future Growth
Future criteria checks 2/6
Arcutis Biotherapeutics is forecast to grow earnings and revenue by 63.1% and 39.3% per annum respectively. EPS is expected to grow by 65.6% per annum. Return on equity is forecast to be -135.7% in 3 years.
Key information
63.1%
Earnings growth rate
65.6%
EPS growth rate
| Biotechs earnings growth | 23.2% |
| Revenue growth rate | 39.3% |
| Future return on equity | -135.7% |
| Analyst coverage | Good |
| Last updated | 24 Apr 2024 |
Recent future growth updates
Recent updates
Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25
Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Dec 18Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis
Sep 26Arcutis Biotherapeutics: A Name To Accumulate
Sep 18Arcutis acquires privately-held biotech Ducentis BioTherapeutics
Sep 07Arcutis launches plaque psoriasis therapy Zoryve in US
Aug 10Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Aug 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 385 | -15 | 104 | N/A | 7 |
| 12/31/2025 | 232 | -145 | -53 | N/A | 7 |
| 12/31/2024 | 116 | -231 | -137 | N/A | 7 |
| 12/31/2023 | 60 | -262 | -247 | -247 | N/A |
| 9/30/2023 | 49 | -268 | -262 | -262 | N/A |
| 6/30/2023 | 11 | -331 | -309 | -286 | N/A |
| 3/31/2023 | 6 | -327 | -304 | -281 | N/A |
| 12/31/2022 | 4 | -311 | -281 | -258 | N/A |
| 9/30/2022 | 1 | -311 | -262 | -238 | N/A |
| 6/30/2022 | N/A | -260 | -212 | -212 | N/A |
| 3/31/2022 | N/A | -235 | -186 | -185 | N/A |
| 12/31/2021 | N/A | -206 | -176 | -175 | N/A |
| 9/30/2021 | N/A | -169 | -156 | -155 | N/A |
| 6/30/2021 | N/A | -150 | -149 | -148 | N/A |
| 3/31/2021 | N/A | -144 | -139 | -138 | N/A |
| 12/31/2020 | N/A | -136 | -113 | -113 | N/A |
| 9/30/2020 | N/A | -114 | -97 | -97 | N/A |
| 6/30/2020 | N/A | -90 | -74 | -74 | N/A |
| 3/31/2020 | N/A | -63 | -57 | -57 | N/A |
| 12/31/2019 | N/A | -42 | -43 | -43 | N/A |
| 9/30/2019 | N/A | -35 | -32 | -32 | N/A |
| 6/30/2019 | N/A | -28 | -24 | -24 | N/A |
| 3/31/2019 | N/A | -23 | -19 | -18 | N/A |
| 12/31/2018 | N/A | -19 | -14 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARQT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARQT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARQT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARQT's revenue (39.3% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: ARQT's revenue (39.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARQT is forecast to be unprofitable in 3 years.